Macé, Sandrine
Inserm · National and Kapodistrian University of Athens · Université de Lille · Centre Hospitalier Universitaire de Lille · Sorbonne Université · Hôpital Saint-Antoine · Istanbul University
3 papers on CoChatORCID 0000-0001-9263-6994
Most cited papers
- Verified
Isatuximab, carfilzomib, and dexamethasone in relapsed multiple myeloma (IKEMA): a multicentre, open-label, randomised phase 3 trial
Moreau, P., Dimopoulos, M.-A., Mikhael, J., Yong, K., Capra, M., Facon, T., Hajek, R., Špička, I., Baker, R., Kim, K., et al. (2021) · The Lancet
Multiple Myeloma Research and TreatmentsChronic Lymphocytic Leukemia Research
Cited by 392
- Verified
Isatuximab, Bortezomib, Lenalidomide, and Dexamethasone for Multiple Myeloma
Facon, T., Dimopoulos, M.-A., Leleu, X. P., Beksac, M., Pour, L., Hájek, R., Liu, Z., Minarik, J., Moreau, P., Romejko-Jarosinska, J., et al. (2024) · New England Journal of Medicine
Multiple Myeloma Research and TreatmentsBone health and treatments
Cited by 284
- Verified
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours
de Weger, V. A., de Jonge, M., Langenberg, M. H. G., Schellens, J. H. M., Lolkema, M., Varga, A., Demers, B., Thomas, K., Hsu, K., Tuffal, G., et al. (2019) · British Journal of Cancer
Cancer-related Molecular PathwaysMelanoma and MAPK Pathways
Cited by 62
Go further with a free account
Verify every reference, keep papers in a library, and ask questions across them.
Sign up - it is free